A Rare Inherited Lupus That Starts Early
Lupus is often described as a disease of adults, and especially of women. A new multicenter study led by researchers at Sultan Qaboos University adds an important exception to that picture. The work focuses on DNASE1L3 deficiency, a rare inherited disorder that can produce systemic lupus erythematosus and hypocomplementemic urticarial vasculitis syndrome at an early age.
The team reports that this form of lupus can begin very young. The median age at diagnosis in their cohort was just five years. It also appears that the condition's long-term consequences may not be captured by the standard measurements used to track disease activity. Even as those scores improved, complications affecting the kidneys, lungs, bones and other organs became more common.
What the DNASE1L3 Gene Does, and What Happens Without It
The DNASE1L3 gene provides instructions for an enzyme whose job is to help clear DNA released from dying cells. Under normal circumstances, that cleanup prevents stray genetic material from lingering in the bloodstream. When the enzyme is deficient, DNA from dying cells can remain in circulation.
Researchers suspect that this leftover material contributes to the formation of immune complexes, clusters of antibodies bound to DNA, which set off chronic inflammation and gradually damage the body's tissues. That mechanism helps explain why DNASE1L3 deficiency can directly cause lupus and related vasculitis, and why damage can be progressive: repeated bouts of inflammation may leave a cumulative mark on organs over time.
The Largest Cohort of Its Kind
The new study, titled "Discordance between disease activity and long-term outcomes in DNASE1L3 deficiency: a multicenter longitudinal cohort study," was published in Lupus Science & Medicine. It followed 57 patients with genetically confirmed DNASE1L3 deficiency from 22 families, all receiving care at pediatric rheumatology centers in Oman and the United Arab Emirates. The researchers describe it as the largest longitudinal cohort of this deficiency reported to date.
Several features of the group stand out:
- Gender: 32 of the patients were male and 25 were female, a near-equal distribution that contrasts with the strong female predominance typically seen in systemic lupus erythematosus.
- Age: the median age at diagnosis was five years, an unusually early onset for lupus.
- Geography: 79% of patients came from Al Sharqiyah Governorate in Oman, and a second cluster was identified in Al Ain, UAE.
- Genetics: most Omani patients shared the same homozygous DNASE1L3 variant, while the UAE cluster carried a different recurrent variant.
Geographic Clustering and Inherited Variants
The concentration of cases in two regions is not simply a matter of where doctors happened to look. It reflects the biology of a rare inherited condition. When the same variant appears in many families in one area, it usually points to a founder effect or to patterns of marriage within a community that make it more likely for two carriers to have children together.
The fact that the Omani and Emirati clusters carried different recurrent variants suggests the disorder arose independently in the two populations rather than spreading from a single source. For clinicians, that regional signal is practical information. It can prompt earlier genetic testing when a young child presents with symptoms that resemble lupus or with a stubborn urticarial vasculitis.
When Disease Activity Scores Improve, Damage Can Still Accumulate
One of the study's central findings is a mismatch between how active the disease appears and how much harm it is doing. Conventional measures of lupus disease activity improved over time in the cohort. Yet the researchers found that kidney, lung, bone and other long-term complications became more common.
This discordance is the reason the paper's title refers to a split between disease activity and long-term outcomes. Activity scores are designed to capture inflammation happening now, including swelling, rashes and blood abnormalities. They are not necessarily designed to measure cumulative organ injury, which can build quietly over years. A child whose laboratory values and symptom scores look better may still be developing scarring in the kidneys, restrictive changes in the lungs, or loss of bone density.
Why Continued Organ Monitoring Matters Into Adulthood
The study's authors emphasize the need for continued organ monitoring into adulthood. Their reasoning follows directly from the data: if damage can accumulate while activity scores say the disease is improving, then relying on activity scores alone could leave complications undetected until they are advanced.
For families, that means regular assessments of kidney function, lung health, bone density and other organ systems may remain important long after the most visible symptoms have settled. For clinicians, it argues for a long view, treating DNASE1L3 deficiency not as a childhood illness that resolves, but as a lifelong condition whose risks shift over time.
What the Findings Mean for Diagnosis and Care
Because DNASE1L3 deficiency is rare, an individual physician may see very few cases across an entire career. The new cohort gives them a clearer reference point. A young child, particularly one from a region where the variant is known to cluster, who develops lupus-like symptoms or hypocomplementemic urticarial vasculitis should be evaluated with the possibility of an inherited cause in mind.
Genetic confirmation matters not only for the patient but for the family. The disorder is inherited, and identifying the specific variant can inform counseling for relatives. The study's identification of distinct recurrent variants in Oman and the UAE adds practical value, because it may help laboratories prioritize which genetic changes to look for in each region.
The Bigger Picture for Lupus Research
DNASE1L3 deficiency is unusual, but it illuminates a broader question in lupus research: how to measure what really matters to patients over decades. Activity and damage are related, yet they are not the same thing. A treatment strategy that suppresses inflammation today may still need to be paired with strategies that protect organs over the long term.
The Sultan Qaboos University-led team's work does not answer every question about how best to prevent that damage. It does, however, establish a large, genetically confirmed, longitudinally followed group in which those questions can be studied. And it makes a case that in this inherited form of lupus, silence is not the same as safety.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
